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INTRODUCTION
Cognitive behavioral therapy for insomnia (CBT-I) is 
commonly regarded as the treatment of choice for persistent 
insomnia disorder.1-3 CBT-I has been shown to be as effective 
as pharmacotherapy in the short term but, in contrast to pharma-
cotherapy, leads to durable improvements in sleep (for up to 2 y 
post-intervention).4 One of the frequently cited advantages of 
CBT-I, and non-pharmacological approaches in general, is the 
absence of or potential for treatment-related adverse effects.5,6 
This is in contrast to pharmacotherapy where, for example, 
negative short- and long-term effects of sedative hypnotics 
have been well described.7-10 Indeed, adverse effects are 
routinely assessed in randomized, placebo-controlled clinical 
SLEEP RESTRICTION THERAPY FOR INSOMNIA AFFECTS SOMNOLENCE AND VIGILANCE
http://dx.doi.org/10.5665/sleep.3386
Sleep Restriction Therapy for Insomnia is Associated with Reduced Objective 
Total Sleep Time, Increased Daytime Somnolence, and Objectively Impaired 
Vigilance: Implications for the Clinical Management of Insomnia Disorder
Simon D. Kyle, MA, PhD1; Christopher B. Miller, BSc2; Zoe Rogers, MSc3; A. Niroshan Siriwardena, PhD4; Kenneth M. MacMahon, DClinPsy, PhD5; 
Colin A. Espie, PhD6
1School of Psychological Sciences, University of Manchester, Manchester, UK; 2Woolcock Institute of Medical Research, University of Sydney, Sydney, 
Australia; 3Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK; 4School of Health and Social Care, University 
of Lincoln, Lincoln, UK; 5Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK; 6Sleep and Circadian Neuroscience Institute, 
University of Oxford, Oxford, UK
Submitted for publication March, 2013
Submitted in final revised form May, 2013
Accepted for publication June, 2013
Address correspondence to: Simon D. Kyle, MA, PhD, Division of Clinical 
Psychology, School of Psychological Sciences, Zochonis Building, Bruns-
wick Street, University of Manchester, England, United Kingdom; E-mail: 
simon.kyle@manchester.ac.uk
Study Objectives: To investigate whether sleep restriction therapy (SRT) is associated with reduced objective total sleep time (TST), increased 
daytime somnolence, and impaired vigilance.
Design: Within-subject, noncontrolled treatment investigation.
Setting: Sleep research laboratory.
Participants: Sixteen patients [10 female, mean age = 47.1 (10.8) y] with well-defined psychophysiological insomnia (PI), reporting TST ≤ 6 h.
Interventions: Patients were treated with single-component SRT over a 4-w protocol, sleeping in the laboratory for 2 nights prior to treatment 
initiation and for 3 nights (SRT night 1, 8, 22) during the acute interventional phase. The psychomotor vigilance task (PVT) was completed at seven 
defined time points [day 0 (baseline), day 1,7,8,21,22 (acute treatment) and day 84 (3 mo)]. The Epworth Sleepiness Scale (ESS) was completed 
at baseline, w 1-4, and 3 mo.
Measurement and results: Subjective sleep outcomes and global insomnia severity significantly improved before and after SRT. There was, 
however, a robust decrease in PSG-defined TST during acute implementation of SRT, by an average of 91 min on night 1, 78 min on night 8, 
and 69 min on night 22, relative to baseline (P < 0.001; effect size range = 1.60-1.80). During SRT, PVT lapses were significantly increased from 
baseline (at three of five assessment points, all P < 0.05; effect size range = 0.69-0.78), returning to baseline levels by 3 mo (P = 0.43). A similar 
pattern was observed for RT, with RTs slowing during acute treatment (at four of five assessment points, all P < 0.05; effect size range = 0.57-0.89) 
and returning to pretreatment levels at 3 mo (P = 0.78). ESS scores were increased at w 1, 2, and 3 (relative to baseline; all P < 0.05); by 3 mo, 
sleepiness had returned to baseline (normative) levels (P = 0.65).
Conclusion: For the first time we show that acute sleep restriction therapy is associated with reduced objective total sleep time, increased daytime 
sleepiness, and objective performance impairment. Our data have important implications for implementation guidelines around the safe and 
effective delivery of cognitive behavioral therapy for insomnia.
Keywords: Adverse effects, CBT, insomnia, sleep restriction therapy, sleepiness, vigilance
Citation: Kyle SD; Miller CB; Rogers Z; Siriwardena AN; MacMahon KM; Espie CA. Sleep restriction therapy for insomnia is associated with 
reduced objective total sleep time, increased daytime somnolence, and objectively impaired vigilance: implications for the clinical management of 
insomnia disorder. SLEEP 2014;37(2):229-237.
trials of hypnotics and guide regulatory approval.11 Somewhat 
surprisingly, adverse effects are almost never systematically 
recorded and/or reported in trials of psychological/behavioral 
treatments.5,12-14
Sleep restriction therapy (SRT), a standard behavioral 
strategy used within multi-component CBT-I2 and as a stand-
alone intervention,6,15,16 involves restricting a patient’s time in 
bed (TIB, sleep window) to match their average (self-report) 
total sleep duration. The sleep window is then titrated, weekly, 
based on sleep efficiency (the proportion of TIB spent asleep), 
in order to arrive at the patient’s core sleep requirement. 
Decreasing the opportunity to sleep over successive nights, it 
is argued, builds homeostatic sleep pressure, stabilizes circa-
dian control of sleep and wakefulness, and dampens presleep 
cognitive and physiological (hyper)arousal, leading to shorter 
sleep latencies and more consolidated, uninterrupted sleep.6,17-20 
CBT-I practitioners often advise patients that, because of the 
reduced opportunity for nighttime sleep, coupled with ‘prohi-
bition’ of daytime napping, increased sleepiness may emerge 
during the initial phases of SRT implementation, resulting in 
a transient worsening of daytime functioning.18,21 Magnitude 
of TIB restriction may also be affected by the well-established 
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objective-subjective sleep discrepancies, known to charac-
terize some patients with insomnia.22-24 That is, patients may 
be assigned TIB prescriptions that are significantly lower than 
pretreatment objective sleep, leading to marked sleep loss over 
several weeks.6 Patients are, therefore, advised not to drive or 
operate heavy machinery if they feel excessively sleepy.18,21
Although these guidelines have evolved from clinical experi-
ence, there has been little systematic investigation of the nature 
or magnitude of CBT-I-induced daytime sleepiness and impair-
ment. When investigating the utility of modafinil as an adjunct 
to CBT-I, Perlis and colleagues25 showed that those receiving 
CBT + placebo (n = 10) reported increased Epworth Sleepiness 
Scale (ESS) scores 1 w post-SRT delivery. In contrast, both the 
therapeutic arm (CBT + modafinil) and additional control group 
(modafinil + contact) did not exhibit such a marked increase 
in ESS scores. Kyle et al.6 conducted the first in-depth exami-
nation of single-component SRT. A mixed-methods approach 
was applied that involved questionnaire-based measures, semi-
structured interviews, and real-time audiodiaries to probe the 
patient experience of treatment. During acute implementation 
of SRT, patients subjectively reported problems with exces-
sive daytime sleepiness, which negatively affected daytime 
functioning beyond pretreatment levels. Of note, more than 
one third of the audiodiary subsample complained, during 
real-time recordings, that driving was adversely affected [e.g.: 
“Woke up bright and breezy, half six, Tuesday morning, raring 
to go, got into the car…and within 20 min I was absolutely 
exhausted, so bad that I swear I was nearly falling asleep all 
the way to work. It was torture, I was cross-eyed, eyes drooping, 
driving”; “driving was a nightmare, and I’ve never ever had 
an issue with driving before”; “I felt, really, I was a danger on 
the road.”]6 Despite these acute difficulties, patients responded 
well to treatment, evidencing robust improvements in sleep 
and daytime functioning at 3 mo follow-up. Recently, Miller et 
al.20 complemented these qualitative findings using ecological 
momentary assessment. The authors reported that point-in-time 
assessments of ‘sleepiness/fatigue’ increased during w 1 of 
SRT, whereas ‘positive mood’ and ‘alert cognition’ decreased, 
relative to baseline.
To date, no study has profiled whether subjective reports of 
treatment-related dysfunction are reflected in objective perfor-
mance impairments. Moreover, it is unclear to what extent sleep 
is actually restricted during SRT and whether this is associated 
with elevated daytime sleepiness, measured with a validated 
instrument. Information on the magnitude and time course of 
sleep loss, daytime sleepiness, and performance impairment 
may have important implications for the future refinement, 
delivery, and safe dissemination of CBT-I.
METHOD
In the current study, 16 patients with psychophysiological 
insomnia (PI) took part in a brief regimen of SRT. In order 
to profile changes in sleep time and objective performance, 
patients slept in the laboratory on five occasions (twice × base-
line, thrice × during acute treatment) and completed a psycho-
motor vigilance task (PVT) at seven defined time points. The 
ESS was also completed on a weekly basis (baseline, w 1-4 and 
at 3 mo) to index changes in daytime somnolence (Figure 
1 provides a schematic description of protocol). A compar-
ison group of good sleepers (n = 15) was recruited in order to 
examine baseline differences in PVT performance.
We hypothesized that acute implementation of SRT would 
lead to reduced total sleep time (TST), which would be accom-
panied by impairments in vigilance (increased attentional 
lapses and slowed reaction time [RT]) and increased daytime 
sleepiness.
Sample
Sixteen thoroughly screened patients with PI were recruited 
to take part in SRT for insomnia disorder. Individuals initially 
responded to media advertisements looking for poor sleepers to 
sleep for 2 nights in the sleep laboratory, as part of a study into 
sleep related attentional bias (grant # R01MH077901). This 
was a noninterventional study, but on completion of the over-
night protocol (see following text for details), those without 
evidence of occult sleep disorder pathology were invited to 
take part in the current treatment study, using SRT. A group 
of healthy age- and sex-matched good sleepers (n = 15) was 
recruited for comparative purposes.
Assessments
Sleep Status
Patients with PI participated in a telephone interview by an 
expert in behavioral sleep medicine to assess the absence of 
comorbidities and medication use, as well as the presence of 
insomnia, defined as satisfying the following criteria for subjec-
tive sleep impairment:
Figure 1—Schematic presentation of study protocol. ESS, Epworth Sleepiness Scale; PSG, polysomnography; PVT, psychomotor vigilance task; R/T, review 
and titrate; SRT, sleep restriction therapy.
[sleep diaries completed throughout]
Baseline Week 1 Week 2 Week 3 Week 4 === Week 12
SRT R/T R/T R/T R/T 
PVT    PVT PVT    PVT PVT    PVT                                                               PVT
ESS ESS ESS ESS ESS ESS
2x PSG PSG  PSG PSG
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• Report of sleep disturbance for at least 3 nights per week 
for at least 6 mo
• Sleep onset latency (SOL) and/or wake after sleep onset 
(WASO) > 30 min
• TST ≤ 6 h
• Sleep efficiency < 85%
• Daytime impairment attributed to disturbed sleep
• Insomnia Severity Index (ISI) score ≥ 15
The phone interview was based on guidelines described 
by Morin and Espie21 and supplemented with a sleep disor-
ders screening questionnaire.26 Those deemed eligible were 
invited to attend a screening day, involving a thorough sleep 
and psychiatric interview (Mini-international Neuropsy-
chiatric Interview27) with a licensed clinical psychologist 
trained in behavioral sleep medicine, and a medical assess-
ment (electrocardiogram, blood chemistries, medical history, 
and drug screening) by a certified physician. Patients meeting 
research diagnostic criteria for PI,28 and who met all other 
inclusion/exclusion criteria, subsequently slept for 2 consecu-
tive nights at the University of Glasgow Sleep Centre where 
they underwent polysomnographic (PSG) assessment (see 
subsequent text).
Good sleepers participated in the same phone interview 
to assess inclusion/exclusion criteria, defined as the absence 
of sleep, psychiatric or (unstable) medical disorder, and the 
endorsement of good quality, restorative sleep, in addition to 
the following:
• SOL and WASO < 15 min
• Number of nighttime awakenings ≤ 2
• TST > 6 h
• Sleep efficiency > 85%
• Stable sleep period between 22:00 and 08:00
All study participants completed a 7-day sleep diary21 to 
assess sleep continuity and quality and help rule out circadian 
phase disturbance. Patients completed sleep diaries for 6 w 
in total (baseline, treatment w 1-4, and at 3 mo). Participants 
also completed the Hospital Anxiety and Depression Scale 
(HADS),29 supplementing the psychiatric screening interview 
and helping to rule out clinical level anxiety/affective disorders. 
Patients completed the ISI,30 a sensitive measure of insomnia 
severity, at baseline, 4 w (posttreatment), and 3 mo. Finally, 
patients completed the ESS31 at six time points (baseline, w 1-4, 
and 3 mo). The standard ESS does not include a specified time 
frame and thus for the purpose of the current study, modifica-
tions were made so that patients completed the ESS with refer-
ence to “in the last week…”, permitting assessment of weekly 
sleepiness levels.
It should be noted that matching between patients and good 
sleepers was initiated on a subject-by-subject basis, with each 
patient matched with a corresponding good sleeper (GS) in 
terms of sex and age ± 2 y. Successful one-to-one matching was 
achieved for 14 of 16 patients.
Polysomnography
A standard PSG montage was used, involving electroenceph-
alographic [EEG: Fp1 (neutral), C3, P3 (reference), O1, Fpz, 
Fz, Cz, Pz, Oz, F4, C4], electrooculographic (EOG: horizontal 
and vertical) and electromyographic (submental) recordings. 
On night 1 of the baseline phase, all participants were screened 
for sleep disordered breathing and periodic limb movements 
through monitoring of abdominal and thoracic effort, nasal 
airflow, oximetry, and bilateral tibialis anterior EMG. Sleep 
was recorded on a Lifelines TrackitTM ambulatory recorder and 
scored visually by two experienced scorers (> 90% interscorer 
reliability) according to criteria by Rechtschaffen and Kales.32 
For study inclusion, patients were required to have an apnea-
hypopnea index and periodic limb movements of sleep arousal 
index < 10. This initial night served as screening and adapta-
tion to the sleep environment, whereas night 2 of the baseline 
phase was used as a comparator to index change during SRT. 
During baseline PSG assessment, patients implemented normal, 
‘at-home’ bed and rise-times (guided by sleep diary records).
For the SRT intervention, patients slept in the sleep laboratory 
on three additional nights (SRT nights 1, 8, and 22; Figure 1) 
where sleep parameters were recorded (EEG, EMG, EOG) 
during implementation of a prescribed sleep window (based on 
sleep diary reports of TST; see details of SRT intervention in 
the following paragraphs). For the purpose of the current study, 
PSG-defined TST was the only selected variable of interest, to 
index magnitude of sleep reduction between baseline and SRT 
nights. Future reports will focus on changes in objective sleep 
continuity parameters, as well as sleep macroarchitecture and 
microarchitecture, in relation to treatment response.
Psychomotor Vigilance Task
The PVT is a frequently used task in sleep research to assess 
the effect of sleep restriction, total sleep deprivation, or altered 
sleep timing on basic vigilant attention. Evidence also exists 
that PVT metrics relate to driving simulator performance 
during sleep deprivation33 and that PVT performance is reliable 
across repeated administrations.34 The version of the PVT used 
in the current study has been applied in studies of insomnia 
and sleep perturbation.35,36 In the task, participants are asked to 
respond with a left mouse click, as quickly as possible, to the 
presence of an asterisk located in the center of the computer 
screen. Interval onset for asterisks varied between 1 and 10 sec 
in duration and there were 110 experimental trials. Participants 
completed five practice trials at the beginning of the session 
to aid task familiarity. The PVT was programmed in E-prime 
(http://www.pstnet.com/eprime.cfm) and completed on a Dell 
laptop computer, at a viewing distance of 40 cm. Task duration 
was approximately 13 min. PVT testing took place at 18:00. 
The following PVT metrics37 were analyzed: (1) attentional 
‘lapses’ (defined as RTs > 500 msec); and (2) 1/Mean RT [lower 
values indicating a slowing in response speed].
Intervention
There are several different variants of SRT used in clinical 
practice, but our intervention was based on the original seminal 
work by Spielman et al.17 and previously published protocols 
from our group.6 Specifically, the SRT intervention involved 
one main session for delivery of treatment rationale and instruc-
tions, and four additional brief, in-person or telephone interac-
tions to review progress and titrate sleep efficiency (Figure 1). 
Treatment was delivered by experts in behavioral sleep medi-
cine via PowerPoint slides to two patients at a time, and covered 
SRT rationale, sleep window calculation, and troubleshooting 
around potential implementation difficulties. The sleep window 
SLEEP, Vol. 37, No. 2, 2014 232 Vigilance and Sleepiness during Sleep Restriction Therapy—Kyle et al
was initially calculated based on 1 w of baseline sleep diaries, 
with TIB prescriptions reflecting average TST. The sleep 
window was subsequently titrated each week according to 
the following guidelines: sleep efficiency < 85%, decrease 
by 15 min; sleep efficiency ≥ 85-89%, no change; and sleep 
efficiency ≥ 90%, increase by 15 min.17 The minimum sleep 
window was set at 5 h. For those patients in whom the sleep 
window was deemed too difficult, restrictive, or impossible 
to adhere to, a compromise was established between therapist 
and the patient. No other components of CBT-I were addressed 
during the intervention. Beyond the 4-w acute interventional 
phase, patients completed sleep diaries and sleep efficiency 
grids and continued to self-titrate the sleep window according 
to the aforementioned sleep efficiency criteria.
The study protocol was reviewed and approved by the West 
of Scotland NHS Research Ethics Committee (protocol no. 10/
SO701/85).
Analysis
Group differences (patients versus good sleepers), with 
respect to demographic and sleep related variables, were assessed 
using independent t-tests. Treatment-related change in subjec-
tive sleep diary outcomes (SOL, WASO, sleep efficiency) and 
insomnia severity (ISI) were assessed with repeated-measures 
analysis of variance (ANOVA), across baseline, posttreatment 
(w 4) and 3-mo follow-up. PSG-TST (min), daytime sleepi-
ness (ESS) and vigilance (lapses, RT) were similarly assessed 
with repeated-measures ANOVA. Logarithmic transformations 
were performed on variables exhibiting skewed distributions. 
For those variables failing to meet the sphericity assump-
tion, degrees of freedom and corresponding probability were 
adjusted using the Greenhouse-Geisser correction. Significant 
main effects were followed up using paired t-tests. PSG-TST 
was compared across 4 nights [baseline (night number 2), and 
treatment nights (1, 8, and 22)], vigilance across seven time 
points [day 0 (baseline), day 1,7,8,21,22 (acute treatment) and 
day 84 (3 mo)] and sleepiness across six time points [baseline, 
w 1-4, 3-mo follow-up]; with comparisons focused on change 
from baseline assessments. Effect sizes (ES) for paired data 
were calculated as follows: [mean difference / standard devia-
tion (SD) of difference]. All comparisons were two-sided, with 
P < 0.05 indicating statistical significance, but given the a priori 
nature of our directed hypotheses, P values and effect size data 
are also reported for P ≤ 0.10.
Although the primary analyses of interest focussed on 
assessment of within-subject change for vigilance, sleepiness 
and PSG-TST, recruitment of a group of good sleepers also 
permitted between-group comparisons at baseline, with respect 
to PVT lapses and RT (using independent t-tests).
RESULTS
Sample
Sixteen patients [10 female, mean age = 47.1 (10.8) y] 
initially enrolled in the study and completed session 1. One 
patient dropped out in the first week due to concerns about the 
effect of SRT on work functioning. The 15 remaining partici-
pants completed the full protocol (five laboratory nights and 
seven neurocognitive assessments), including 12-w follow-up. 
Mean age of the remaining 15 patients was 47.2 y (SD = 10.4) 
and 10 (66.6%) were female. The comparison group of good 
sleepers were identical in both age (47.1, SD = 10.5) and sex 
(10 female [66.6%]). As expected, patients with PI demon-
strated significant sleep disturbance at baseline relative to GS 
(Table 1), and reported greater levels of anxiety and depression. 
Of note, and consistent with the diagnosis of PI, anxiety and 
depression scores were in the mild range and approximate those 
found in large nonclinical samples.38
Subjective Sleep: Manipulation Check of the SRT Protocol
The average prescribed sleep window for the first week of 
therapy was 347.0 min (SD = 32.0), which increased by 15 min 
over the 4-w acute SRT phase (w 4 = 362.0 min, SD = 33.0; 
Figure 2). Sleep diary records of TIB decreased from a baseline 
of 483.2 min (SD = 74.1) to 353.2 min (SD = 36.1) during w 
1, in line with prescribed sleep window times, indicating close 
adherence to the SRT protocol (Figure 2).
Insomnia severity (measured with the ISI) significantly 
reduced across assessment points [F(2,24) = 85.07, P < 0.001), 
decreasing from 17.4 (SD = 2.8) at baseline to 7.7 (SD = 3.9) 
at 4 w (P < 0.001). Further reductions were observed between 
w 4 and 3 mo (5.08, SD = 4.1; P = 0.004, and P < 0.001 for 
comparison with baseline). Subjective reports of SOL simi-
larly changed over assessment period [F(1.04,11.39) = 16.24, 
P = 0.002], reducing from 32.2 (SD = 21.8) min at base-
line to 9.4 min (SD = 5.4) at 4 w (P < 0.01) and remaining 
at this level (8.1, SD = 5.2) at 3-mo follow-up. Both WASO 
and sleep efficiency showed robust changes over time 
[WASO: F(1.04,11.41) = 9.04, P = 0.011 and sleep efficiency: 
F(1.07,11.75) = 28.34, P < 0.001]. WASO significantly reduced 
from 66.8 (SD = 60.7) min at baseline to 12.4 min (SD = 10.1; 
P = 0.01) at posttreatment, remaining at this level at 3 mo 
(16.2 min, SD = 16.7). Changes in WASO and SOL were 
reflected in improved sleep efficiency, increasing from 68.0% 
Table 1—Demographic and sleep characteristics for patients with 
psychophysiological insomnia and good sleepers
GS (n = 15) PI (n = 16)
Age (SD) 47.1 (10.5) 47.1 (10.8)
Sex% (F:M) 66.7/33.3 62.5/37.5
ISI 0.8 (1.1) 17.8a (2.8)
HADS-A 2.1 (2.3) 6.4a (4.0)
HADS-D 0.9 (1.6) 4.0a (2.2)
SOL (min) 7.1 (7.9) 38.8a (32.4)
WASO (min) 6.8 (11.2) 62.6a (58.8)
No. Awak 1.2 (1.4) 2.1b (1.3)
TST (min) 449.9 (41.7) 338.7a (57.4)
TIB (min) 503.1 (51.0) 490.6 (66.8)
SE (%) 89.9 (6.3) 69.3a (12.3)
SQ (0-4) 3.3 (0.4) 1.7a (0.6)
GS, good sleepers; HADS-A/D, Hospital Anxiety and Depression 
Scale; ISI, Insomnia Severity Index; No. Awak, number of awakenings; 
PI = psychophysiological insomnia; SE, sleep efficiency; SOL, sleep 
onset latency; SQ, sleep quality; TIB, time in bed; TST, total sleep time; 
WASO, wake after sleep onset. aP < 0.01, bP < 0.10 for group comparison.
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(SD = 13.7) at baseline, to 90.7% (SD = 4.4; P < 0.001) at 4 w, 
which was maintained at 3 mo (91.3%, SD = 4.8). Finally, 
subjective TST estimates showed fluctuation over assessment 
points [F(2,22) = 13.04, P = 0.001]. Although there was no 
change in TST between baseline and posttreatment (326.8, 
SD = 61.1 versus 334.9, SD = 37.1; P = 0.50), by 3 mo TST had 
improved by approximately 56 min, to 383.2 min (SD = 49.3; 
P < 0.01 for baseline comparison).
PVT Performance
PVT performance was first compared across GS (n = 15) and 
patients with PI (n = 15; pretreatment). Independent t-tests did 
not reveal any significant baseline group differences for number 
of attentional lapses [PI = 7.4 (SD = 7.2) versus GS = 7.2 
(SD = 10.7); t = 0.49, P = 0.62] or 1/mean RT [PI = 2.87 
(SD = 0.30) versus GS = 3.03 (SD = 0.36); t = 1.31, P = 0.20].
Changes in patient PVT performance across the treat-
ment protocol [days 0, 1, 7, 8, 21, 22, 84] were next exam-
ined with repeated-measures ANOVA. A main effect of time 
was observed for attentional lapses [F(6,84) = 4.45, P = 0.001] 
and a significant quadratic trend [F(1,14) = 30.52, P < 0.001; 
Figure 3]. Relative to baseline (day 0), number of lapses 
increased (nonsignificantly) at day 1 (P = 0.10; ES = 0.45) and 
7 (P = 0.075; ES = 0.50), and were significantly elevated at 
days 8 (P = 0.010; ES = 0.77), 21 (P = 0.009; ES = 0.78) and 
22 (P = 0.018; ES = 0.69) of SRT. By day 84 (3 mo), lapses 
returned to baseline levels [3 mo = 7.0 (SD = 8.7) versus base-
line = 7.4 (SD = 7.2); P = 0.43).
Similar findings were observed for RT, reflected in a signifi-
cant main effect of time [F(6,84) = 3.11, P = 0.008], accompa-
nied by a significant quadratic trend [F(1,14) = 7.59, P = 0.015; 
Figure 4]. Relative to baseline (day 0), patient RTs increased at 
day 1 (P = 0.042; ES = 0.58), day 8 (P = 0.045; ES = 0.57), day 
21 (P = 0.034; ES = 0.61) and day 22 (P = 0.004; ES = 0.89). 
By day 84 (3 mo), RTs had returned to baseline levels (2.85, 
SD = 0.35 versus 2.87, SD = 0.30; P = 0.78).
Daytime Sleepiness
Sleepiness evidenced a significant main effect of time 
[F(5,60) = 7.26, P < 0.001] and a significant quadratic trend 
[F(1,12) = 11.58, P = 0.005; Figure 5]. ESS scores signifi-
cantly increased from baseline to w 1 [4.95, SD = 3.02 versus 
8.69, SD = 4.96; P = 0.004, ES = 0.98], w 2 [9.08, SD = 5.84; 
P = 0.006, ES = 0.92], and w 3 [7.85, SD = 5.8; P = 0.035, 
ES = 0.66]. There were no significant differences between 
ESS scores at baseline and w 4 (6.85, SD = 5.18; P = 0.112) 
or between baseline and week 12 (3.80, SD = 4.96; P = 0.652).
PSG-Defined TST
We next assessed the magnitude of change in PSG-TST, from 
the baseline PSG night (pretreatment) relative to SRT acute 
implementation, and the extent to which TST varied across the 
three SRT laboratory nights (nights 1, 8, and 22). There was 
Figure 2—Descriptive profiles of mean (± standard error) sleep window 
prescriptions (w 1-4) and sleep-diary reported time in bed (TIB) over the 
course of sleep restriction therapy protocol.
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(RTs > 500 msec) over the course of sleep restriction therapy (SRT). 
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a significant main effect of time [F(3,39) = 27.03, P < 0.001; 
Figure 6]. Baseline TST was 393.6 min (SD = 43.0), which 
decreased by 91 min on the first night of SRT (302.4, SD = 53.0; 
P < 0.001, ES = 1.62), remaining significantly reduced at night 
8 (315.6, SD = 26.7; P < 0.001, ES = 1.80) and night 22 (324.6, 
SD = 34.6; P < 0.001, ES = 1.60). TST exhibited a trend toward 
improving between night 1 and 22 (by approximately 22 min; 
P = 0.052, ES = 0.57).
DISCUSSION
CBT-I is widely regarded as the most effective treatment 
option for chronic insomnia. Similar to psychological therapies 
in other fields, CBT-I is promoted as a safe and adverse-effect-
free intervention. Our clinical and research experience suggests 
that CBT components, particularly SRT, may be associated 
with some negative effects, but examination and evidence are 
lacking.6,21 Understanding possible treatment-related adverse 
effects has important implications for patient care. In the 
current study, we aimed to quantify the effect of SRT on objec-
tively defined vigilance, daytime sleepiness, and objective TST.
The first thing to note is that our SRT intervention effec-
tively improved the core symptoms of insomnia. That is, by 
w 4, diary ratings of SOL, WASO, and SE had all improved 
relative to baseline (with corresponding large effects). Changes 
in sleep diary parameters were also reflected in reduced ratings 
of overall insomnia severity. These findings were maintained 
(or enhanced) at 3 mo follow-up. Of course, our aim was not 
to test the effectiveness of SRT per se, but results from our 
(uncontrolled) work support the growing literature that SRT is 
an effective, single-component intervention.15,16 Furthermore, 
improvements in sleep, coupled with reductions in diary-
reported TIB during SRT—almost overlapping with prescribed 
sleep window times—suggests that patients followed the 
protocol faithfully.
Despite these posttreatment improvements in sleep conti-
nuity and insomnia severity, PVT performance was found to 
deteriorate during acute SRT implementation, reflected in a 
greater number of attentional lapses and slowed RT. To our 
knowledge, this is the first evidence that SRT (or any component 
of CBT-I) is associated with objective performance impair-
ment. Performance was impaired on three of five assessment 
points for attentional lapses and four of five assessment points 
for reaction time, relative to baseline (medium-to-large effects). 
By 3 mo, performance had returned to baseline levels. Consis-
tent with meta-analytic data,39 patients did not differ from GS 
at baseline with respect to PVT performance; therefore, in this 
study sample and protocol, insomnia per se was not associated 
with impaired vigilance, but acute treatment was.
Deterioration in PVT performance was paralleled by 
increased daytime sleepiness as reflected in ESS scores. 
Patients reported significantly elevated ESS scores during w 
1-3 of treatment (medium-to-large effects). By 3 mo, however, 
and similar to PVT performance, ESS scores had returned 
to baseline levels. A reduction in TST is the most intuitive 
explanation for degraded performance and increased sleepi-
ness during treatment. Comparing PSG nights, we observed a 
large reduction in TST by approximately 91 min on SRT night 
1, 78 min on night 8, and 69 min on SRT night 22. Chronic 
sleep restriction protocols in healthy subjects, even with sleep 
curtailment of just 1.5 h, reveal cumulative impairments in PVT 
performance over a 14-day period.40,41 Although we were not 
able to assess vigilance or objective sleep on a daily basis, it is 
interesting that RT performance appears to follow a relatively 
linear (cumulative) decline throughout the acute phase of SRT, 
with impairments tending to be most pronounced on days 8, 21, 
and 22. It is also clear that PSG-defined TST is relatively stable 
over the 3 assessment nights (increasing by 22 min from night 
1 to night 22), and the prescribed sleep window was extended 
by just 15 min over the entire 4-w treatment protocol (Figure 2).
Our findings are difficult to compare with published litera-
ture because few studies have investigated the acute phase of 
insomnia treatment; instead, tending to focus on pretreatment 
to posttreatment outcomes. Previous work by our group6,20 and 
others17,25,42,43 provide both systematic and clinical evidence of 
treatment-related difficulties, including self-reported sleepi-
ness, cognitive impairment, and implementation challenges, 
but longitudinal tracking of sleep and functioning is lacking. 
Treatment studies that have used PSG to assess sleep outcomes, 
before and after CBT-I, have not found convincing evidence of 
change in TST4 and, to our knowledge, no published study has 
Figure 5—Mean (± standard error) Epworth Sleepiness Scale (ESS) 
scores throughout treatment weeks. **P < 0.01, *P < 0.05 for comparison 
with baseline.
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examined the magnitude of PSG-defined TST reduction during 
acute implementation (although TIB reduction, similar to our 
study, has been shown to exceed 2 h).17 However, inspection 
of published CBT-I trial data, where both objective (PSG) and 
subjective (sleep diary) baseline data are reported, indicates 
that TST discrepancies often range between 50 and 60 min44-46 
(indeed, in one study, as high as 83 min)46; and it is well known 
that a general objective-subjective sleep discrepancy exists in 
some patients with insomnia.23,24,47 This discrepancy has impor-
tant implications for sleep window calculation and the degree 
to which patients may be sleep restricted during, and possibly 
after, CBT treatment monitoring.
On this point, Morin and colleagues48 reported that PSG-
defined TST was significantly reduced (medium-to-large effect) 
in the CBT treatment arm at 6 w (post-treatment), and Buysse 
et al.49 reported significant reductions in actigraphy-defined 
TST relative to an information-only control group after 4 w 
of brief behavioral therapy (SRT + stimulus control therapy). 
Thus, it would appear that TST reduction during CBT-I is 
likely the norm, rather than the exception, but the field lacks 
consistent (week-by-week) process data to answer this ques-
tion definitively. An important point is that TST appears to 
return to at least baseline levels during follow-up PSG assess-
ments,45,46,48,50 suggesting that CBT exerts its therapeutic effect, 
at least in part, through correction or restoration of sleep-wake 
perception.44 Priming sleep pressure through TST reduction 
may also be necessary to overcome cognitive arousal and 
consolidate sleep,6,19,20,51 but these putative mechanistic routes 
require further experimental attention. Importantly, there exists 
the possibility that some patients, perhaps treatment nonre-
sponders, continue to implement SRT for a prolonged period of 
time which, if associated with chronic sleep restriction, could 
have detrimental health effects.52
Limitations
Our findings must be interpreted within the context of 
several limitations. Principally, our sample size was small 
and we did not include an untreated (patient) control group. 
This limitation is partially mitigated through triangulation of 
methodologies (PSG, performance impairment, self-reported 
sleepiness), coupled with normalized trajectories of sleepiness 
and vigilance, at follow-up, giving us some confidence in our 
conclusions. Nevertheless, we cannot conclude with certainty 
that SRT was responsible for the observed effects. Recruit-
ment of a group of patients with untreated insomnia, a group 
receiving another CBT-I component or an inactive interven-
tion should be considered in future research studies. We also 
realize that SRT is often introduced within the context of a full 
CBT-I package and so our results may not generalize to all 
CBT-based interventions. An important point to remember is 
that SRT is commonly introduced in the second or third session 
of CBT-I protocols53-56 and as such the sleep window may not 
be calculated based on pre-treatment diary values, but instead 
from sleep parameters measured during the first 2 w of CBT-I. 
This would potentially lead to longer sleep window prescrip-
tions, because sleep may already be improving, than if the 
sleep window were based on pre-treatment data. However, this 
remains an empirical question that could be addressed through 
reanalysis of existing datasets.
Moreover, our SRT protocol may not generalize to all CBT-
based approaches that include a sleep restriction component, 
because we (1) recruited patients reporting ≤ 6 h TST and (2) 
there are many variants of SRT (e.g., some involve prescribing 
a sleep window based on TST plus 30 min,50 whereas others 
may permit daytime napping45), which may differentially affect 
sleepiness and vigilance. Nevertheless, our SRT protocol, 
although shorter in duration, was based on guidelines set forth 
by Spielman et al.,17 which are commonly implemented in clin-
ical practice and CBT-I trials.
A related point to consider is that in-laboratory SRT, due to 
increased monitoring and strict scheduling of the sleep window, 
may have led to greater adherence and possibly enhanced 
impairment. In practice, it is likely that patients tend to modify 
the duration and timing of the sleep window (in the home envi-
ronment) based on individual preferences and ability to func-
tion. Nevertheless, it is important to understand the full effect of 
SRT when patients adhere faithfully to the prescribed program. 
Convergence of diary-recorded TIB and prescribed sleep 
window durations (Figure 2) would support this conclusion. 
It is also worth noting that vigilance was impaired relative to 
baseline, regardless of whether patients had slept, the previous 
night, in the laboratory or at home; ruling out the possibility 
that performance was impaired simply because of the labora-
tory environment.
In the current study our intention was to isolate SRT, 
because this intervention has been found to be very effective 
(when used in single-component interventions), yet difficult 
to implement,43 and our early work suggested the possibility 
of treatment-related impairment.6,20 It is worth pointing out, 
however, that stimulus control therapy may also be associated 
with acute sleep loss, and possible impairment. Future work 
should attempt to characterize the magnitude and time course of 
stimulus-control-related impairment (in isolation) as well as in 
combination with SRT, because many programs combine these 
two behavioral interventions.49,53-57
Finally, because we did not assess performance beyond 
3 w (or sleepiness beyond 4 w), during the acute treatment 
phase, we cannot determine exactly when vigilance started to 
normalize. From ESS data it would appear that, by w 4, sleepi-
ness was beginning to weaken, but future work should profile 
daytime performance (including objective measures of sleep 
debt, e.g., Multiple Sleep Latency Test) for several weeks 
beyond active treatment/monitoring. The negative effects were 
most pronounced in our study within the first 3 w but it is worth 
noting that CBT-I and classic SRT, according to Spielman 
et al.,17 often last for 6-8 w, reinforcing the need to extend 
measurement beyond the 3-4 w in our trial.
Clinical Implications
We think it reasonable, even mandatory, to reflect on what 
might be the clinical impact of our results. Assuming there is 
a “necessary pain to achieve gain” with SRT, clinicians should 
emphasize that CBT-I may negatively affect vigilance levels, 
and those that are identified as excessively sleepy, pretreatment, 
or appear to report gross subjective-objective sleep discrepan-
cies, should be assigned a more liberal sleep window. There 
currently exists variation in the minimum TIB sleep window 
used in SRT, as well as variation in time in bed calculation and 
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titration method.18 The field should aim to reach a consensus 
on what is the recommended SRT protocol as well as any 
required modifications for specific populations (e.g., cancer, 
major depression, bipolar disorder, comorbid chronic pain).55,58 
Consensus should be guided by experimental manipulations, 
which are needed to reveal treatment mechanisms6,20 and to 
provide empirical data on the ‘dose’ of sleep restriction required 
to bring about treatment response. Related to this, the suitability 
and feasibility of using objective measures to guide sleep 
window generation and titration should also be considered.
Finally, we realize that some laboratories and therapists set 
a minimum TIB as low as 4.5 h.17,58 Indeed, had we set this as 
our minimum TIB, three participants would have been assigned 
a 4.5-h sleep window and another patient 4.75 h. It remains 
possible that minimum TIB as low as 4.5 h may lead to impair-
ment greater than that observed in the current study. Going 
forward, the standardization of SRT procedures, often regarded 
as the most effective ingredient of CBT-I interventions, should 
be considered a research and clinical priority for Behavioral 
Sleep Medicine specialists.
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